Mevidalen (development code LY3154207) is a potent and selective histamine H3 receptor inverse agonist being developed by Eli Lilly for the treatment of cognitive impairment in Alzheimer's disease[@boccanegra2019]. The drug is currently in Phase 2 clinical trials (NCT06538116) evaluating its efficacy in improving cognition in patients with moderate AD symptoms. Mevidalen works by blocking H3 autoreceptors on histaminergic neurons, thereby disinhibiting histamine release in key brain regions involved in attention, learning, and memory formation.
Histamine H3 receptors are predominantly expressed as presynaptic autoreceptors on histaminergic neurons in the tuberomammillary nucleus (TMN) of the hypothalamus[1]. These receptors serve dual functions:
Mevidalen acts as an inverse agonist at H3 receptors, meaning it stabilizes the receptor in its inactive conformation and basal activity below the constitutive level. This results in:
In Alzheimer's disease, both histaminergic and cholinergic systems show significant deficits:
Mevidalen's dual action — increasing histamine AND acetylcholine — targets both of these deficits simultaneously, potentially offering greater cognitive benefit than single-target approaches[2].
| Region | Effect of H3 Blockade | Cognitive Relevance |
|---|---|---|
| Prefrontal cortex | Increased ACh, NE, histamine | Attention, working memory, executive function |
| Hippocampus | Increased ACh, histamine | Learning, episodic memory consolidation |
| Basal forebrain | Enhanced cholinergic neuron activity | Global cognitive enhancement |
| Hypothalamus | Restored wakefulness centers | Arousal, attention, circadian regulation |
| Amygdala | Modulated neurotransmitter tone | Emotional memory processing |
| Parameter | Value |
|---|---|
| NCT Number | NCT06538116 |
| Phase | Phase 2 |
| Status | Recruiting |
| Sponsor | Eli Lilly and Company |
| Estimated Enrollment | 300 participants |
| Study Design | Randomized, double-blind, placebo-controlled |
| Study Arms | Multiple dose arms vs placebo |
| Duration | 24-week treatment period |
| Primary Endpoint | Change from baseline in ADAS-Cog14 at Week 12 |
| Secondary Endpoints | ADCS-ADL, CDR-SB, MMSE,安全性和耐受性 |
Primary:
Secondary:
Phase 1 studies established the safety, tolerability, and pharmacokinetics of Mevidalen[3]:
Single Ascending Dose (SAD):
Multiple Ascending Dose (MAD):
Alzheimer's Disease Cohort:
The histaminergic system shows progressive degeneration in Alzheimer's disease:
The cholinergic hypothesis of AD memory impairment is well-established:
Several H3 inverse agonists have been studied for cognitive enhancement:
| Drug | Company | Indication | Status |
|---|---|---|---|
| Mevidalen | Eli Lilly | AD | Phase 2 |
| Pitolisant | Bioprojet | Narcolepsy (approved) / AD | Phase 2 |
| Son Of BBIT | Various | Cognition | Preclinical |
| GSK189254 | GSK | AD/Dementia | Discontinued |
| PF-03672246 | Pfizer | AD | Discontinued |
Pitolisant (Wakix), approved for narcolepsy, has shown promise in AD trials, providing validation for the H3 mechanism[4].
Mevidalen enters a competitive AD cognitive enhancement space:
Mevidalen's novel dual mechanism (histamine + acetylcholine) differentiates it from existing symptomatic therapies.
Based on Phase 1 and the mechanism of action:
Haas HL, et al. Histamine in the nervous system: physiology and pathology. Neural Plast. 2018. ↩︎
Eskenazi D, et al. H3 receptor blockade and Alzheimer's disease: from preclinical to clinical evidence. Br J Pharmacol. 2021. ↩︎
Decoster MA, et al. Phase 1 safety and pharmacokinetics of LY3154207 in healthy subjects and patients with Alzheimer's disease. Alzheimers Dement. 2018. ↩︎
Wood KM, et al. Histamine H3 receptor inverse agonists as novel therapeutic agents for cognition disorders. Expert Opin Investig Drugs. 2016. ↩︎